Results 251 to 260 of about 57,349 (269)

Cap-independent co-expression of dsRNA-sensing and NF-κB pathway inhibitors enables tunable self-amplifying RNA expression with reduced immunotoxicity

Lim TK, Ritoux A, Paine LW, Ferguson L, Abdul T, Grundy LJ, Smith ESJ.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Polyplex nanomicelle delivery of self-amplifying RNA vaccine

Journal of Controlled Release, 2021
Self-amplifying RNA (SaRNA) is a burgeoning platform that exploits the replication machinery of alphaviruses such as Venezuelan equine encephalitis (VEE) virus or Sindbis virus (SIN). SaRNA has been used for development of human vaccines, but has not been evaluated for porcine vaccine development.
Yi-Hao, Chang, Mei-Wei, Lin, Ming-Chen, Chien, Guan-Ming, Ke, I-En, Wu, Ren-Li, Lin, Chin-Yu, Lin, Yu-Chen, Hu   +7 more
openaire   +4 more sources

Self-amplifying RNA COVID-19 vaccine

Cell
In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.
Christopher J, Wayne, Anna K, Blakney
openaire   +4 more sources

Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine?

Nature Reviews Drug Discovery, 2012
openaire   +3 more sources

Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine

2023
AbstractIn order to improve vaccine effectiveness and safety profile of existing synthetic RNA-based vaccines, we have developed a self-amplifying RNA (saRNA)-based vaccine expressing membrane-anchored receptor binding domain (RBD) of SARS-CoV-2 S protein (S-RBD) and have demonstrated that a minimal dose of this saRNA vaccine elicits robust immune ...
Mai Komori, Amber L. Morey, Andrés A. Quiñones-Molina, Josiane Fofana, Luis Romero, Elizabeth Peters, Kenta Matsuda, Suryaram Gummuluru, Jonathan F. Smith, Wataru Akahata, Hisashi Akiyama   +10 more
openaire   +2 more sources

Self-amplifying RNA virus vectors for drug delivery

Expert Opinion on Drug Delivery
Viral vectors have proven useful for delivering genetic information, such as drugs and vaccines, for therapeutic and prophylactic interventions. Self-amplifying RNA viruses possess the special feature of high-level RNA amplification in the host cell cytoplasm providing high antigen production against infectious pathogens and various types of cancers ...
openaire   +2 more sources

Delivery Vehicles for Self-amplifying RNA

2022
Nuthan Vikas Bathula, Petya Popova, Anna Blakney   +2 more
openaire   +1 more source

Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA

The recent COVID-19 pandemic as well as other past and recent outbreaks of newly or re-emerging viruses show the urgent need to develop potent new vaccine approaches, that enable a quick response to prevent global spread of infectious diseases. The breakthrough of first messenger RNA (mRNA)-based vaccines 2019 approved only months after identification ...
Louisa, Zimmermann, Stephanie, Erbar
openaire   +2 more sources

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

EClinicalMedicine, 2022
Katrina M Pollock, Alexander J Szubert, David Owen   +2 more
exaly  

The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency

Journal of Controlled Release, 2022
Craig W Roberts, Gustavo Lou, Stuart Woods   +2 more
exaly